The life sciences community can't agree on whether the U.S. should restrict or embrace China's booming biotech sector. Chinese assets are projected to make up over two-thirds of total pharma deal value in 2026, up from just 5% five years ago. Some warn this hollows out American innovation; others say restricting access only hurts U.S. patients.
The U.S. biopharma world is at a crossroads. Chinese assets are now the dominant source of licensing deals for Western pharma companies — projected to account for more than two-thirds of total industry deal value in 2026, up from 42% last year and just 5% five years ago. It's cheaper and faster to do early-stage drug development in China, and giants like Bristol Myers Squibb and Pfizer are following the money.
But not everyone is on board. Critics warn that directing capital toward China starves American frontier biotech of the funding it needs, risks hollowing out the domestic innovation base, and won't stop China from eventually competing head-to-head with U.S. pharma. On the other side, industry groups like PhRMA argue that restricting access to Chinese science doesn't help patients — it just cedes control to China.
Policymakers are stepping in too. The House Select Committee on China is investigating drug manufacturers' clinical trials at Chinese military sites, and legislation has been introduced to screen outbound biotech investments under the COINS framework.
Key Takeaways:
Why it matters: The debate isn't just about business strategy — it touches on national security, patient access, and the long-term future of American biotech leadership. How Washington and industry resolve this tension will shape where the next generation of medicines comes from.
